OMIDRIA- phenylephrine and ketorolac injection, solution, concentrate

Omidria by

Drug Labeling and Warnings

Omidria by is a Prescription medication manufactured, distributed, or labeled by Rayner Surgical Inc., Patheon Manufacturing Services LLC, Hospira. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

  • 2 DOSAGE AND ADMINISTRATION

    Omidria must be diluted prior to intraocular use. For administration to patients undergoing cataract surgery or intraocular lens replacement, 4 mL of Omidria is diluted in 500 mL of ocular irrigating solution. Irrigation solution is to be used as needed for the surgical procedure for a single patient.

    The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions.

    Do not use if the solution is cloudy or if it contains particulate matter.

  • 3 DOSAGE FORMS AND STRENGTHS

    Omidria is an intraocular solution containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac for use in a single patient.

  • 4 CONTRAINDICATIONS

    Omidria is contraindicated in patients with a known hypersensitivity to any of its ingredients.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Elevated Blood Pressure

    Systemic exposure to phenylephrine can cause elevations in blood pressure.

    5.2 Cross-Sensitivity or Hypersensitivity

    There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti- inflammatory drugs (NSAIDs). There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac in patien ts who either have a known hypersensitivity to aspirin/NSAIDs or a past medical history of asthma. Therefore, use Omidria with caution in individuals who have previously exhibited sensitivities to these drugs.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Studies Experience

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

    Table 1 shows frequently reported ocular adverse reactions with an incidence of ≥ 2% of adult patients as seen in the combined clinical trial results from three randomized, placebo-controlled studies [see Clinical Studies ( 14)] .

    Table 1: Ocular Adverse Reactions Reported by ≥ 2% of Adult Patients
    MedDRA Preferred TermPlacebo

    (N=462)     		Omidria

    (N=459)
    n (%)n (%)
    Ocular Events
    Anterior Chamber Inflammation102 (22%)111 (24%)
    Intraocular Pressure Increased15 (3%)20 (4%)
    Posterior Capsule Opacification16 (4%)18 (4%)
    Eye Irritation6 (1%)9 (2%)
    Foreign Body Sensation in Eyes11 (2%)8 (2%)

    In a safety study that enrolled 72 pediatric patients up to 3 years old, no overall difference in safety was observed between pediatric and adult patients.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    There are no available data on Omidria use in pregnant women or animals to inform
    any drug-associated risks. Oral administration of ketorolac to rats during late
    gestation produced dystocia and increased pup mortality at a dose 740-times the
    plasma exposure at the recommended human ophthalmic dose (RHOD). Since
    human systemic exposure to Omidria following a lens replacement procedure is low
    (see Clinical Pharmacology (12.3)], the applicability of animal findings to the risk
    of Omidria in humans during pregnancy is unclear. Omidria should be used during
    pregnancy only if the potential benefit justifies the potential risk to the fetus.
    Clinical Considerations
    Fetal/Neonatal Adverse Reactions
    Premature closure of the ductus arteriosus in the fetus has occurred with third
    trimester use of oral and injectable NSAIDs. Ketorolac plasma concentrations are
    detectable following ocular Omidria administration [see Clinical Pharmacology (12.3)].
    The use of Omidria during late pregnancy should be avoided.
    .Q.a1a
    Animal Data
    No well-controlled animal reproduction studies have been conducted with Omidria
    or phenylephrine.
    Ketorolac, administered during organogenesis, did not cause embryofetal abnormalities
    or mortalities in rabbits or rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day,
    respectively. These doses produced systemic exposure that is 1150 times and
    4960 times the plasma exposure (based on Cma,c) at the RHOD, respectively. When
    administered to rats during late gestation (after Day 17 of gestation) at oral doses
    up to 1.5 mg/kg/day (740 times the plasma exposure at the RHOD), ketorolac
    produced dystocia and increased pup mortality.

    Risk Summary

    There are no available data on Omidria use in pregnant women or animals to inform any drug-associated risks. Oral administration of ketorolac to rats during late gestation produced dystocia and increased pup mortality at a dose 740-times the plasma exposure at the recommended human ophthalmic dose (RHOD). Since human systemic exposure to Omidria following a lens replacement procedure is low [ see Clinical Pharmacology ( 12.3) ], the applicability of animal findings to the risk of Omidria in humans during pregnancy is unclear. Omidria should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Clinical Considerations

    Fetal/Neonatal Adverse Reactions

    Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Ketorolac plasma concentrations are detectable following ocular Omidria administration [see Clinical Pharmacology ( 12.3)] . The use of Omidria during late pregnancy should be avoided.

    Data

    Animal Data

    No well-controlled animal reproduction studies have been conducted with Omidria or phenylephrine.

    Ketorolac, administered during organogenesis, did not cause embryofetal abnormalities or mortalities in rabbits or rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses produced systemic exposure that is 1150 times and 4960 times the plasma exposure (based on C max) at the RHOD, respectively. When administered to rats during late gestation (after Day 17 of gestation) at oral doses up to 1.5 mg/kg/day (740 times the plasma exposure at the RHOD) , ketorolac produced dystocia and increased pup mortality.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of Omidria in human milk, the effects on the breastfed infant, or the effects on milk production. Howerver, systemic exposure to Omidria, following a lens replacement procedure is low [see Clinical Pharmacology ( 12.3)] . The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omidria and any potential adverse effects on the breastfed child from Omidria.

    8.4 Pediatric Use

    The safety and effectiveness of Omidria have been established in the pediatric population from neonates to adolescents (birth to younger than 17 years). Use of Omidria in this population is supported by evidence from adequate and well-controlled studies of Omidria in adults with additional data from a single active-controlled safety study in pediatric patients up to 3 years old [see Clinical Studies ( 14)] .

    No overall differences in safety were observed between pediatric and adult patients.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness have been observed between elderly and adult patients.

  • 10 OVERDOSAGE

    Systemic overdosage of phenylephrine may cause a rise in blood pressure. It may also cause headache, anxiety, nausea, vomiting, and ventricular arrhythmias. Supportive care is recommended.

  • 11 DESCRIPTION

    Omidria is a sterile aqueous solution, containing the α 1-adrenergic receptor agonist phenylephrine HCl and the nonsteroidal anti-inflammatory ketorolac tromethamine, for addition to ocular irrigating solution.

    The descriptions and structural formulae are:

    Phenylephrine Hydrochloride Drug Substance:

    Common Name:phenylephrine hydrochloride
    Chemical Name:(-)- m-Hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride
    Molecular Formula:C 9H 13NO 2 · HCl
    Molecular Weight:203.67 g/mole

    Figure 1: Chemical Structure for Phenylephrine HCl

    Figure 1

    Ketorolac Tromethamine Drug Substance:

    Common Name:ketorolac tromethamine
    Chemical Name:(±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
    Molecular Formula:C 15H 13NO 3 · C 4H 11NO 3
    Molecular Weight:376.40 g/mole

    Figure 2: Chemical Structure for Ketorolac Tromethamine

    Figure 2

    Omidria is a clear, colorless to slightly yellow, sterile solution concentrate with a pH of approximately 6.3.

    Each vial of Omidria contains:

    Actives: phenylephrine hydrochloride 12.4 mg/mL equivalent to 10.16 mg/mL of phenylephrine and ketorolac tromethamine 4.24 mg/mL equivalent to 2.88 mg/mL of ketorolac.

    Inactives: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The two active pharmaceutical ingredients (API) in Omidria, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis, and reducing postoperative pain.

    Phenylephrine is an α 1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris. Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac, by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, also prevents surgically induced miosis.

    12.3 Pharmacokinetics

    In a pharmacokinetic study evaluating Omidria, systemic exposure to both phenylephrine and ketorolac was low or undetectable.

    A single-dose of Omidria as part of the irrigation solution was administered in 14 patients during lens replacement surgery. The volume of irrigation solution used during surgery ranged between 150 mL to 300 mL (median 212.5 mL). Detectable phenylephrine plasma concentrations were observed in one of 14 patients (range 1.2 to 1.4 ng/mL) during the first 2 hours after the initiation of Omidria administration. The observed phenylephrine plasma concentrations could not be distinguished from the preoperative administration of phenylephrine 2.5% ophthalmic solution prior to exposure to Omidria.

    Ketorolac plasma concentrations were detected in 10 of 14 patients (range 1.0 to 4.2 ng/mL) during the first 8 hours after the initiation of Omidria administration. The maximum ketorolac concentration was 15 ng/mL at 24 hours after the initiation of Omidria administration, which may have been due to application of postoperative ketorolac ophthalmic solution.

  • 14 CLINICAL STUDIES

    Studies in Adults

    The efficacy and safety of Omidria were evaluated in two Phase 3, randomized, multicenter, double-masked, placebo-controlled clinical trials in 808 adult patients undergoing cataract surgery or intraocular lens replacement.

    Patients were randomized to either Omidria or placebo. Patients were treated with preoperative topical mydriatic and anesthetic agents. Pupil diameter was measured throughout the surgical procedure. Postoperative pain was evaluated by self-administered 0-100 mm visual analog scales (VAS).

    Mydriasis was maintained in the Omidria-treated groups while the placebo-treated groups experienced progressive constriction.

    Figure 3: Intraoperative Pupil Diameter (mm) Change-from-Baseline

    Figure 3

    At the end of cortical clean-up, 23% of placebo-treated patients and 4% of Omidria-treated patients had a pupil diameter less than 6 mm (p < 0.01).

    Pain during the initial 10-12 hours postoperatively was statistically significantly less in the Omidria-treated groups than in the placebo-treated groups.

    Figure 4: Postoperative Mean Visual Analog Scale (VAS) Scores for Pain

    Figure 4

    During the 10-12 hours postoperatively, 26% of Omidria-treated patients reported no pain (VAS = 0 at all timepoints) while 17% of placebo-treated patients reported no pain (p < 0.01).

    Study in Pediatric Patients

    The safety of Omidria was evaluated in a single, randomized, multicenter, double-masked, active-controlled clinical study in 72 pediatric patients up to 3 years old undergoing cataract surgery with or without intraocular lens replacement.

    Patients were randomized to either Omidria or phenylephrine. Patients were treated with preoperative topical mydriatic and anesthetic agents. As in the adult studies, mydriasis was maintained in the Omidria-treated group. No overall differences in safety were observed between pediatric and adult patients.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution, for addition to ocular irrigating solution.

    Omidria is supplied in a multi-pack containing:

    4 vials : NDC: 82604-600-04 or

    1 vials: NDC: 82604-600-00

    Storage: Store at 20˚ to 25˚C (68˚ to 77˚F). Protect from light.

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients that they may experience sensitivity to light.

    Rayner Surgical Inc.

    Suite 102, 14335 NE 24 Street
    Bellevue, WA 98007

    © Rayner 2023


    Patented product; see www.rayner.com/patents for further details.

    OMIDRIA®and the OMIDRIA® Logo are registered trademarks of Rayner Surgical Inc.


    640069

  • PRINCIPAL DISPLAY PANEL

    NDC: 82604-600-04

    OMIDRIA®

    (phenylephrine and ketorolac intraocular solution)

    1% / 0.3%

    For Intraocular use.

    Must Be Diluted.

    Single-Patient vial

    Sterile 4 mL

    Quantity: 4

    Rx Only

    omi00-0003-05

    NDC: 82604-600-00

    OMIDRIA ®

    (phenylephrine and ketorolac intraocular solution)

    1% / 0.3%

    For Intraocular use.

    Must Be Diluted.

    Single-Patient vial

    Sterile 4 mL

    Quantity: 1

    Rx Only

    omi00-0003-06

  • INGREDIENTS AND APPEARANCE
    OMIDRIA 
    phenylephrine and ketorolac injection, solution, concentrate
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 82604-600
    Route of AdministrationINTRAOCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHENYLEPHRINE (UNII: 1WS297W6MV) (PHENYLEPHRINE - UNII:1WS297W6MV) PHENYLEPHRINE 10.16 mg  in 1 mL
    KETOROLAC (UNII: YZI5105V0L) (KETOROLAC - UNII:YZI5105V0L) KETOROLAC 2.88 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)  
    WATER (UNII: 059QF0KO0R)  
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 82604-600-001 in 1 CARTON07/01/2023
    14 mL in 1 VIAL; Type 0: Not a Combination Product
    2NDC: 82604-600-044 in 1 CARTON07/01/2023
    24 mL in 1 VIAL; Type 0: Not a Combination Product
    3NDC: 82604-600-994 in 1 CARTON07/01/2023
    34 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20538807/01/2023
    Labeler - Rayner Surgical Inc. (118502278)
    Establishment
    NameAddressID/FEIBusiness Operations
    Patheon Manufacturing Services LLC079415560manufacture(82604-600)
    Establishment
    NameAddressID/FEIBusiness Operations
    Hospira093132819manufacture(82604-600)

    • Trademark Results [Omidria]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    OMIDRIA
    OMIDRIA
    86123592 4740003 Live/Registered
    Omeros Corporation
    2013-11-19
    OMIDRIA
    OMIDRIA
    86123589 4740002 Live/Registered
    Omeros Corporation
    2013-11-19
    OMIDRIA
    OMIDRIA
    85912133 4732094 Live/Registered
    Omeros Corporation
    2013-04-23
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.